Navigation Links
Cell-permeable peptide shows promise for controlling cardiovascular disease
Date:4/17/2013

Philadelphia, PA, April 16, 2013 Atherosclerosis sometimes called "hardening of the arteries" is a leading cause of death and morbidity in Western countries. A cell-permeable peptide containing the NF-ĸB nuclear localization sequence (NLS) shows promise as a potential agent in controlling the development of atherosclerotic disease. This study is published in the May 2013 issue of The American Journal of Pathology.

Atherosclerosis is a chronic inflammatory disease of the arterial and vascular wall. The objective of many therapeutic compounds is to modulate atherogenesis the process that leads to the formation of fatty tissue-containing plaques that stick to the cell wall. Numerous cellular and molecular inflammatory components are involved in the disease process, and uncontrolled activation of pro-inflammatory transcription factors, such as nuclear factor-B (NF-ĸB), plays a significant role. Several NF-ĸB inhibitors are in phase II-III clinical trials against various inflammatory diseases, but most cardiovascular research is still in the preliminary laboratory experimental phase.

Investigators in Spain, the United States, the United Kingdom, and Germany studied the anti-inflammatory and atheroprotective effects of a cell-permeable peptide containing the NF-ĸB NLS. In vitro tests clearly established that NLS peptide blocks the nuclear import of activated NF-ĸB and inhibits NF-ĸB activation in vascular cells. These findings were corroborated in vivo in ApoE knockout mice, an experimental model relevant to human atherosclerosis. In these experiments, the mice were fed a high-fat diet and treated with either NLS peptide or vehicle (control group).

The results showed that systemic administration of NLS peptide reduced the nuclear NF-ĸB activity in vascular smooth muscle cells (VSMCs) and macrophages of aortic plaques of mice. More importantly, NLS peptide inhibited lesion development in mice either at the onset of atherosclerosis (early treatment) or after the development of advanced plaques (delayed treatment), without affecting serum cholesterol levels. The results also demonstrated that NLS peptide alters plaque composition and inflammation in atherosclerotic lesions.

"The NF-ĸB system is a crucial factor regulating the expression of genes in different steps of the atherosclerotic process, from early phases characterized by lipid modification, chemotaxis, adhesion of leukocytes, monocyte differentiation, foam cell formation, and inflammatory cytokine expression to more advanced lesions involving cell death, migration and proliferation of VSMCs, and fibrous cap formation," explained lead investigator Carmen Gomez-Guerrero, PhD, of the Renal and Vascular Inflammation Laboratory, IIS-Fundacin Jimnez Daz, Autonoma University, Madrid, Spain.

"Our study demonstrates that targeting NF-ĸB nuclear translocation hampers inflammation and atherosclerosis development and identifies cell-permeable NLS peptide as a potential anti-atherosclerotic agent," she said. "These properties make cell-permeable NLS peptide a promising prevention/intervention strategy to inhibit inflammation in cardiovascular diseases."


'/>"/>

Contact: David Sampson
ajpmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. A new avenue to better medicines: Metal-peptide complexes
2. Under the right conditions, peptide blocks HIV infection at multiple points along the way
3. Unique peptide could treat cancers, neurological disorders, and infectious diseases
4. Genetic survey of endangered Antarctic blue whales shows surprising diversity
5. University of Houston study shows BP oil spill hurt marshes, but recovery possible
6. Weakness can be an advantage in surviving deadly parasites, a new study shows
7. Study shows unified process of evolution in bacteria and sexual eukaryotes
8. Sexual reproduction brings long-term benefits, study shows
9. UCSB study shows forest insects and diseases arrive in US via imported plants
10. Study shows botanical formula fights prostate cancer
11. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... Scientists propose in Nature blocking a molecule ... maybe other lysosomal storage diseases as a possible treatment ... An international research team led by ... investigators from the University of Lübeck in ... study was conducted in mouse models of lysosomal storage ...
(Date:2/22/2017)... ... 2017 , ... LabRoots , the leading provider of educational and interactive ... to announce the launch of a new scholarship for young scientists seeking a degree ... scholarship is open to all high school seniors, 17 years or older; as well ...
(Date:2/22/2017)... ... February 22, 2017 , ... NDA Partners Chairman Carl ... Deputy Director in the FDA CDRH Division of Cardiovascular, Respiratory, and Neurological Devices ... as an Expert Consultant. , In Dr. Spyker’s accomplished career, he held positions ...
(Date:2/21/2017)... 2017 Synthetic Biologics, Inc. (NYSE MKT: SYN), ... to protect and restore the health of patients, intends to report ... 2016 on Thursday, March 2, 2017, and to host a conference ... for the call is as follows: U.S. (toll free): ... ...
Breaking Biology Technology: